Recent Finacing
Recent Raise
Iterum develops sulopenem, oral and IV penem antibiotic active against Gram-negative pathogens including ESBL E. coli and K. pneumoniae, with QIDP designations and advancing Phase 3 UTI and IAI trials.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors